Acquisition by Patrick Walsh of 15000 shares of Oil Dri subject to Rule 16b-3
| IMUX Stock | USD 1.10 0.08 7.84% |
Slightly above 55% of Immunic's investors are presently thinking to get in. The analysis of overall sentiment of trading Immunic stock suggests that some investors are interested at this time. Immunic's investing sentiment can be driven by a variety of factors including economic data, Immunic's earnings reports, geopolitical events, and overall market trends.
Immunic |
Filed transaction by Oil Dri Officer Vp, Human Resources. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Immunic Fundamental Analysis
We analyze Immunic's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunic using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunic based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Retained Earnings
Retained Earnings Comparative Analysis
Immunic is currently under evaluation in retained earnings category among its peers. Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
Immunic Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Immunic stock to make a market-neutral strategy. Peer analysis of Immunic could also be used in its relative valuation, which is a method of valuing Immunic by comparing valuation metrics with similar companies.
Peers
Immunic Related Equities
| STTK | Shattuck Labs | 10.74 | ||||
| CCCC | C4 Therapeutics | 7.10 | ||||
| FHTX | Foghorn Therapeutics | 4.58 | ||||
| KZR | Kezar Life | 4.41 | ||||
| GBIO | Generation Bio | 3.60 | ||||
| KRON | Kronos Bio | 3.09 | ||||
| EWTX | Edgewise Therapeutics | 2.55 | ||||
| SPRB | Spruce Biosciences | 2.38 | ||||
| KYMR | Kymera Therapeutics | 1.71 | ||||
| ERAS | Erasca | 1.48 | ||||
| NRIX | Nurix Therapeutics | 1.03 | ||||
| GLUE | Monte Rosa | 0.84 | ||||
| EYEN | Eyenovia | 8.33 |
Additional Tools for Immunic Stock Analysis
When running Immunic's price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.